Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA

DOI 10.1001/jama.289.13.1681

Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 114 references

Research works printed but not linked: 9

Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
Not Available, 2001, Cardiovascular Trials Review
Not Available, 2002, Cardiovascular Trials Review

Sorted by citations

Items 501–600 of 1,001

Diabetes Mellitus Reduces the Clearance of Atorvastatin Lactone
Dostálek, M., Sam, W. J., Paryani, K. R., Macwan, J. S., Gohh, R., & Akhlaghi, F. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261933 · Cited by 32
Rhabdomyolysis with atorvastatin and fusidic acid
O’Mahony, C., Campbell, V. L., Alkhayatt, M., & Brull, D. J. (2008) · Postgraduate Medical Journal · doi:10.1136/pgmj.2007.064097 · Cited by 31
Rhabdomyolysis associated with the nutritional supplement Hydroxycut
Dehoney, S. B., & Wellein, M. G. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070640 · Cited by 31
In vivo anti-hyperlipidemic activity of the triterpene from the stem bark of Protorhus longifolia (Benrh) Engl
Machaba, K. E., Cobongela, S. Z. Z., Mosa, R. A., Oladipupo, L. A., Djarova, T. G., & Opoku, A. R. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-131 · Cited by 31
Disorders of Lipid Metabolism
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
Statin‐disclosed acid maltase deficiency
Voermans, N. C., Lammens, M. M. Y., Wevers, R. A., Hermus, A. R. M. M., & van Engelen, B. G. M. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01515.x · Cited by 31
Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective
Benner, J. S., Smith, T. W., Klingman, D., Tierce, J. C., Mullins, C. D., Pethick, N., & O’Donnell, J. C. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00055.x · Cited by 31
Statin and fibrate associed myopathy: study of eight patients
Carvalho, A. A. S., Lima, Ü. W. P., & Valiente, R. A. (2004) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2004000200013 · Cited by 31
Liquid chromatography–tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma
Wang, J., Luzum, J. A., Phelps, M. A., & Kitzmiller, J. P. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.12.029 · Cited by 30
Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil
Bergman, E., Lundahl, A., Fridblom, P., Hedeland, M., Bondesson, U., Knutson, L., & Lennernäs, H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029363 · Cited by 30
Differential Association Between Statin Exposure and Elevated Levels of Creatine Kinase
Chan, J., Hui, R. L., & Levin, E. G. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g035 · Cited by 30
A Peculiar Formula of Essential Amino Acids Prevents Rosuvastatin Myopathy in Mice
D’Antona, G., Tedesco, L., Ruocco, C., Corsetti, G., Ragni, M., Fossati, A., Saba, E., Fenaroli, F., Montinaro, M., Carruba, M. O., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6582 · Cited by 30
Ezetimibe-related myopathy: A systematic review
Slim, H. B., & Thompson, P. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.08.430 · Cited by 30
Self-citation
Severe Rhabdomyolysis as a Consequence of the Interaction of Fusidic Acid and Atorvastatin
Magee, C. N., Medani, S. A., Leavey, S. F., Conlon, P. J., & Clarkson, M. R. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.07.011 · Cited by 30
Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?
Huddy, K., Dhesi, P., & Thompson, P. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0301-9 · Cited by 30
Self-citation
Transcriptional deficits in oxidative phosphorylation with statin myopathy
Hubal, M. J., Reich, K. A., Biase, A. D., Bilbie, C., Clarkson, P. M., Hoffman, E. P., & Thompson, P. D. (2011) · Muscle & Nerve · doi:10.1002/mus.22081 · Cited by 29
Self-citation
Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease
McCullough, P. A., & Verrill, T. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2119 · Cited by 30
The hepatoprotective effect of the combination use of Fructus Schisandrae with statin – A preclinical evaluation
Wat, E., Ng, C., Wong, E. C. W., Koon, C. M., Lau, C. P., Cheung, D. W. S., Fung, K., Lau, C. B., & Leung, P. C. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.12.004 · Cited by 31
Cost Effectiveness of Rosuvastatin in Treating Patients to Low-Density Lipoprotein Cholesterol Goals Compared With Atorvastatin, Pravastatin, and Simvastatin (a US Analysis of the STELLAR Trial)
Miller, P. S. J., Smith, D. G., & Jones, P. J. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.074 · Cited by 30
Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences
Skilving, I., Eriksson, M., Rane, A., & Ovesjö, M.-L. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2105-2 · Cited by 28
Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins
Shi, Z., & Han, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41629 · Cited by 37
Low plasma vitamin D levels and muscle-related adverse effects in statin users.
Eisen, A., Lev, E., Iakobishvili, Z., Porter, A., Brosh, D., Hasdai, D., & Mager, A. (2014) · PubMed · Cited by 29
Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes
Smith, R. L., Solberg, R., Jacobsen, L. L., Voreland, A. L., Rustan, A. C., Thoresen, G. H., & Johansen, H. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085721 · Cited by 29
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 29
Continuity of Nursing Care in Patients with Coronary Artery Disease: A Systematic Review
Posadas-Collado, G., Membrive‐Jiménez, M. J., Romero‐Béjar, J. L., Gómez‐Urquiza, J. L., Albendín‐García, L., Suleiman‐Martos, N., & la Fuente, G. A. C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053000 · Cited by 29
GATM locus does not replicate in rhabdomyolysis study
Floyd, J. S., Bis, J. C., Brody, J. A., Heckbert, S. R., Rice, K. M., & Psaty, B. M. (2014) · Nature · doi:10.1038/nature13629 · Cited by 29
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
Ho, C. K. M., & Walker, S. W. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611428486 · Cited by 29
Consumer behavior in the setting of over-the-counter statin availability: Lessons from the Consumer Use Study of OTC Mevacor
Brass, E. P. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.07.051 · Cited by 29
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
de Langen, J. J., & van Puijenbroek, E. (2006) · PubMed · Cited by 29
Rhabdomyolysis and Renal Failure Associated with Gemfibrozil Monotherapy
Layne, R. D., Sehbai, A. S., & Stark, L. J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d282 · Cited by 29
Safety of 50,000-100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance
Glueck, C. J., Jetty, V., Wang, P., Shah, P. R., Prince, M., Lee, K., Goldenberg, M., & Kumar, A. (2016) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.179133 · Cited by 28
Oxidative stress as a possible mechanism of statin-induced myopathy
Ahmadi, Y., Ghorbanihaghjo, A., Naghizadeh, M., & Yagin, N. L. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0469-x · Cited by 28
Rhabdomyolysis related to acute recreational drug toxicity—A Euro-DEN study
Waldman, W., Kabata, P. M., Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., Dargan, P. I., & Anand, J. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246297 · Cited by 28
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Li, J., Du, H., Wang, Y., Aertgeerts, B., Guyatt, G. H., Hao, Q., Shen, Y., Li, L., Su, N., Delvaux, N., et al. (2022) · Heart · doi:10.1136/heartjnl-2021-320556 · Cited by 29
Secondary prevention strategies for coronary heart disease
Weiner, S. D., & Rabbani, L. E. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0381-8 · Cited by 28
Mitochondrial Dysfunction Induced by Statin Contributes to Endothelial Dysfunction in Patients with Coronary Artery Disease
Dai, Y.-L., Luk, T.-H., Siu, C., Yiu, K., Chan, H.-T., Lee, S. W. L., Li, S.-W., Tam, S., Fong, B. M.-W., Lau, C., et al. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9071-1 · Cited by 29
The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise
Robinson, M. M., Hamilton, K. L., & Miller, B. F. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00343.2009 · Cited by 28
Role of Thyroid Disease in the Development of Statin-Induced Myopathy
Rush, J., Danzi, S. E., & Klein, I. L. (2006) · The Endocrinologist · doi:10.1097/01.ten.0000240960.40281.2b · Cited by 28
Drug-induced Hyperbilirubinemia and the Clinical Influencing Factors
Ah, Y., Kim, Y., Kim, M., Choi, Y. H., Park, K. H., Son, I.-J., & Kim, S. G. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530802341133 · Cited by 28
Drug–drug interaction with statins
Corsini, A., & Bellosta, S. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.1.105 · Cited by 28
Statin-associated focal myositis
Asbach, P., Paetsch, I., Stawowy, P., Sander, B., & Fleck, E. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.08.109 · Cited by 28
Safety of Statins When Response is Carefully Monitored: A Study of 336 Heart Recipients
Marzoa‐Rivas, R., Crespo-Leiro, M. G., Paniagua-Marin, M. J., Llinares-García, D., Muñiz, J., Aldama‐López, G., Piñón-Esteban, P., Campo-Pérez, R., & Castro-Beiras, A. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.09.163 · Cited by 28
What Is Pharmacoepidemiology?
Strom, B. L. (2019) · Pharmacoepidemiology · doi:10.1002/9781119413431.ch1 · Cited by 31
Discovery of DF-461, a Potent Squalene Synthase Inhibitor
Ichikawa, M., Ohtsuka, M., Ohki, H., Ota, M., Haginoya, N., Itoh, M., Shibata, Y., Sugita, K., Ishigai, Y., Terayama, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400151c · Cited by 27
Communicating statin evidence to support shared decision-making
Barrett, B. P., Ricco, J. A., Wallace, M., KIEFER, D. M., & Rakel, D. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0436-9 · Cited by 27
Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus
Beard, A., Hofer, T. P., Downs, J. R., Lucatorto, M. A., Klamerus, M. L., Holleman, R. G., & Kerr, E. A. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966697 · Cited by 27
An Approach to Myopathy for the Primary Care Clinician
Domingo-Horne, R. M., & Salajegheh, M. K. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.10.016 · Cited by 27
A Comparison of Pectin, Polyphenols, and Phytosterols, Alone or in Combination, to Lovastatin for Reduction of Serum Lipids in Familial Hypercholesterolemic Swine
Metzger, B. T., Barnes, D. M., & Reed, J. D. (2009) · Journal of Medicinal Food · doi:10.1089/jmf.2008.0140 · Cited by 27
Statin Use and Cancer Risk: An Epidemiologic Review
Friis, S., & Olsen, J. H. (2006) · Cancer Investigation · doi:10.1080/07357900600705532 · Cited by 27
The use of statins potentiates the insulin-sensitizing effect of exercise training in obese males with and without Type 2 diabetes
Meex, R. C. R., Phielix, E., Schrauwen‐Hinderling, V. B., Moonen‐Kornips, E., Schaart, G., Schrauwen, P., & Hesselink, M. K. C. (2010) · Clinical Science · doi:10.1042/cs20100153 · Cited by 27
Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin With Rapamycin Plus Tacrolimus in Liver Transplant Patient
Dopazo, C., Bilbao, I., Lázaro, J. L., Sapisochín, G., Caralt, M., Blanco, L., Castells, L., & Charco, R. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.02.019 · Cited by 27
Intracellular cholesterol accumulation and coenzyme Q10 deficiency in Familial Hypercholesterolemia
Suarez-Rivero, J. M., de la Mata, M., Pavón, A. D., Paz, M. V., Povea-Cabello, S., Cotán, D., Álvarez-Córdoba, M., Villalón-García, I., Ybot‐González, P., Salas, J. J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.009 · Cited by 27
Lipid and Non-lipid Effects of Statins
Paoletti, R., Bolego, C., & Cignarella, A. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_13 · Cited by 27
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature
McKelvie, P. A., & Dennett, X. (2002) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200206000-00002 · Cited by 27
Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats
Obayashi, H., Nezu, Y., Yokota, H., Kiyosawa, N., Mori, K., Maeda, N., Tani, Y., Manabe, S., & Sanbuissho, A. (2011) · The Journal of Toxicological Sciences · doi:10.2131/jts.36.445 · Cited by 26
High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans
RYAN, T. E., Torres, M. J., Lin, C., Clark, A. H., Brophy, P. M., Smith, C. A., Smith, C. D., Morris, E. M., Thyfault, J. P., & Neufer, P. D. (2024) · JCI Insight · doi:10.1172/jci.insight.174125 · Cited by 27
Effects of Statin Therapy on Exercise Levels in Participants in the National Runners' and Walkers' Health Study
Williams, P. T., & Thompson, P. D. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.019 · Cited by 26
Self-citation
Intermediate-Term Efficacy and Tolerance of Statins in Children
Mamann, N., Lemale, J., Karsenty, A., Dubern, B., Girardet, J.-P., & Tounian, P. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.03.032 · Cited by 26
Geographic Variation in Statin Use for Complex Acute Myocardial Infarction Patients
Brooks, J. M., Cook, E. A., Chapman, C. G., Kulchaitanaroaj, P., Chrischilles, E. A., Welch, S., & Robinson, J. G. (2014) · Medical Care · doi:10.1097/mlr.0b013e3182a7fc3d · Cited by 26
Statin intolerance
Sikka, P., Kapoor, S., Bindra, V., Sharma, M., Vishwakarma, P., & Saxena, K. K. (2011) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.90085 · Cited by 25
Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Conforti, A., Chiamulera, C., Moretti, U., Colcera, S., Fumagalli, G. F., & Leone, R. (2007) · Current Drug Safety · doi:10.2174/157488607779315516 · Cited by 26
A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients
Sai, K., Kajinami, K., Akao, H., Iwadare, M., Sato-Ishida, R., Kawai, Y., Takeda, K., Tanimoto, T., Yamano, T., Akasaka, T., et al. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.09.002 · Cited by 26
Preventive effects of bicarbonate on cerivastatin-induced apoptosis
Kobayashi, M., Kaido, F., Kagawa, T., Itagaki, S., Hirano, T., & Iseki, K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.010 · Cited by 26
Prediction of Severe Adverse Drug Reactions Using Pharmacogenetic Biomarkers
Tohkin, M., Ishiguro, A., Kaniwa, N., Saito, Y., Kurose, K., & Hasegawa, R. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.122 · Cited by 26
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis
Neuhaus, O., & Hartung, H. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.547 · Cited by 26
Rhabdomyolysis with Cardiac Involvement and Acute Renal Failure in a Patient Taking Rosuvastatin and Fenofibrate
Ireland, J. H. E., Eggert, C. H., Arendt, C. J., & Williams, A. W. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-11-200506070-00020 · Cited by 26
The cerivastatin withdrawal crisis: a “post-mortem” analysis
Maggini, M., Raschetti, R., Traversa, G., Bianchi, C., Caffari, B., Cas, R. D., & Panei, P. (2004) · Health Policy · doi:10.1016/j.healthpol.2004.04.001 · Cited by 26
Effect of Coenzyme Q10Supplementation in Statin-Treated Obese Rats
Choi, H.-K., Won, E.-K., & Choung, S.-Y. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.089 · Cited by 24
Addressing Statin Adverse Effects in the Clinic
Katz, D. H., Intwala, S., & Stone, N. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414529622 · Cited by 27
Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments
Laaksonen, R., Jänis, M. T., & Orešič, M. (2008) · Angiology · doi:10.1177/0003319708321106 · Cited by 25
Perioperative statin therapy
Chan, W. W., Wong, G. T., & Irwin, M. G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.782003 · Cited by 25
The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials
Alsheikh-Ali, A. A. A., & Karas, R. H. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0016-8 · Cited by 25
Self-citation
Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions
Trapani, L., Melli, L., Segatto, M., Trezza, V., Campolongo, P., Jozwiak, A., Swiezewska, E., Pucillo, L. P., Moreno, S., Fanelli, F., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-184218 · Cited by 25
Increased incidence of Merkel cell carcinoma among younger statin users
Sahi, H., Koljonen, V., Böhling, T., Neuvonen, P. J., Vainio, H., Lamminpää, A., Kyyrönen, P., & Pukkala, . (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.05.006 · Cited by 25
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Filippatos, T. D., & Elisaf, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.593509 · Cited by 25
Influence of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Ubiquinone Levels in Rat Skeletal Muscle and Heart: Relationship to Cytotoxicity and Inhibitory Activity for Cholesterol Synthesis in Human Skeletal Muscle Cells
Yamazaki, H., Suzuki, M., Aoki, T., Morikawa, S., Maejima, T., Sato, F., Sawanobori, K., Kitahara, M., Kodama, T., & Saitō, Y. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.295 · Cited by 25
Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors
Ichikawa, M., Yokomizo, A., Itoh, M., Sugita, K., Usui, H., Shimizu, H., Suzuki, M., Terayama, K., & Kanda, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.065 · Cited by 25
Simvastatin represses protein synthesis in the muscle-derived C2C12cell line with a concomitant reduction in eukaryotic initiation factor 2B expression
Tuckow, A. P., Jefferson, S. J., Kimball, S. R., & Jefferson, L. S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00383.2010 · Cited by 25
Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study
Krasuski, R. A., Doeppenschmidt, D., Henry, J. S., Smith, P. B., Adinaro, J. T., Beck, R. L., & Thompson, C. M. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.9.1163 · Cited by 25
Molecular Basis for Statin-Induced Muscle Toxicity: Implications and Possibilities
Buettner, C., & Lecker, S. H. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1133 · Cited by 25
Overprescribing of lipid lowering agents
Smith, M. A. (2006) · BMJ Quality & Safety · doi:10.1136/qshc.2005.016162 · Cited by 25
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals
Dugu, A., Bagheri, H., Lapeyre‐Mestre, M., Tournamille, J., Sailler, L., Dedieu, G., Salvayre, R., Thouvenot, J. P., Massip, P., & Montastruc, J. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0760-1 · Cited by 25
Fluvastatin
Corsini, A., Jacobson, T. A., & Ballantyne, C. M. (2004) · Drugs · doi:10.2165/00003495-200464120-00004 · Cited by 26
Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure
Baber, U., Toto, R. D., & de Lemos, J. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.042 · Cited by 25
Rhabdomyolysis Caused by Commiphora mukul , a Natural Lipid-Lowering Agent
Bianchi, A., Cantù, P., Firenzuoli, F., Mazzanti, G., Menniti‐Ippolito, F., & Raschetti, R. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d486 · Cited by 25
Lipid Metabolism and Health
Moffatt, R. J., & STAMFORD, B. A. (2005) · CRC Press eBooks · doi:10.1201/9781420038422 · Cited by 25
Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin
Page, S. R., & Yee, K. C. (2014) · Internal Medicine Journal · doi:10.1111/imj.12464 · Cited by 24
Safety and Efficacy of Statin Therapy in Patients Switched From Cyclosporine A to Sirolimus After Cardiac Transplantation
Aliabadi, A. Z., Mahr, S., Dunkler, D., Grömmer, M., Zimpfer, D., Wolner, E., Grimm, M. W., & Zuckermann, A. O. (2008) · Transplantation · doi:10.1097/tp.0b013e3181910eb2 · Cited by 23
Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration
Schryver, N. D., Wittebole, X., den Bergh, P. V., Haufroid, V., Goffin, E. J., & Hantson, P. E. (2015) · Case Reports in Nephrology · doi:10.1155/2015/761393 · Cited by 24
Ultrasound diagnosis of bilateral quadriceps tendon rupture after statin use.
Nesselroade, R. D., & Nickels, L. C. (2010) · PubMed Central · Cited by 24
Dynamic Contrast–Enhanced MRI of OATP Dysfunction in Diabetes
Shuboni‐Mulligan, D. D., Parys, M., Blanco‐Fernandez, B., Mallett, C. L., Schnegelberger, R. D., Takada, M., Chakravarty, S., Hagenbuch, B., & Shapiro, E. M. (2018) · Diabetes · doi:10.2337/db18-0525 · Cited by 24
SAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
Simvastatin disrupts cytoskeleton and decreases cardiac fibroblast adhesion, migration and viability
Copaja, M., Venegas, D., Aránguiz, P., Canales, J., Vivar, R., Avalos, Y., Garcı́a, L., Chiong, M., Olmedo, I., Catalán, M., et al. (2012) · Toxicology · doi:10.1016/j.tox.2012.01.011 · Cited by 24
Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite
Narwal, R., Akhlaghi, F., Åsberg, A., Hermann, M., & Rosenbaum, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535980-000000000-00000 · Cited by 24
Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment
Takeshita, M., Katsuragi, Y., Kusuhara, M., Higashi, K., Miyajima, E., Mizuno, K., Mori, K., Obata, T., Ohmori, R., Ohsuzu, F., et al. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.05.009 · Cited by 25
Rational for statin use in psoriatic patients
Mosiewicz, J., Pietrzak, A., Chodorowska, G., Trojnar, M. P., Szepietowski, J. C., Reich, K., & Rizzo, M. (2013) · Archives of Dermatological Research · doi:10.1007/s00403-013-1374-1 · Cited by 24
Necrotizing Myopathies
Quinn, C. C., Salameh, J. S., Smith, T. W., & Souayah, N. (2015) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000065 · Cited by 24
The mevalonate pathway as a metabolic requirement for autophagy–implications for growth control, proteostasis, and disease
Miettinen, T. P., & Björklund, M. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1143546 · Cited by 25
The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study
Spoendlin, J., Layton, J. B., Mundkur, M. L., Meier, C., Jick, S. S., & Meier, C. R. (2016) · Drug Safety · doi:10.1007/s40264-016-0462-5 · Cited by 24
Secondary Stroke Prevention Strategies for the Oldest Patients
Bushnell, C., & Colon-Emeric, C. S. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00003 · Cited by 25

Authors: Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations: Hartford Hospital (US)
ORCID: Thompson, Paul D.
Karas, Richard H.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2003-04-02
Volume: 289
Issue: 13
Pages: 1681
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.289.13.1681
OpenAlex: W2059078444
Cited by: 1,463
References: 114
Citations by year: 2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI: 19.53
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords: statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms: Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin-Associated Myopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks